Clinical Trial Update: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating subcutaneous isatuximab with weekly carfilzomib and dexamethasone in adults with relapsed and/or refractory multiple myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Plasma Cell Myeloma Refractory | Phase 2 | Status: RECRUITING